Article | October 1, 2021

Ensuring Drug Accountability In Clinical Trials

By Sarah Beale, MasterControl

iStock-647243650-vial-syringe-glove-hand

Drug accountability in clinical trials is pretty much what you’d expect. It holds the organizations and people involved in the trial accountable for how they handled the drug being used. Improper drug accountability places the entire clinical trial at risk. Pharmaceutical companies, and regulators, can’t be assured the results of the trial are accurate if there’s information missing from the drug accountability record. This is a critical part of the requirement from 21 CFR Part 312 to maintain adequate records of the disposition of the drug. In some cases, this comes down to simple math. If your records show you provided a subject with 40 pills and he or she somehow took 42, that’s an issue. That might be simple math but ensuring proper drug accountability is far from simple. It requires forethought and consistency to be done properly.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Pharmaceutical Online